Cigna Earnings Call Highlights Growth, EPS Upgrade

Cigna ((CI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cigna’s latest earnings call struck a confident tone, with management emphasizing strong revenue and earnings growth, a higher full‑year EPS outlook, and momentum in core healthcare and specialty businesses. While acknowledging pressure in Pharmacy Benefit Services, special charges, and portfolio pruning, executives framed these as intentional steps to sharpen focus and support long‑term value.

Strong Consolidated Results and Higher EPS Outlook

Cigna reported Q1 2026 revenue of $68.5 billion and adjusted EPS of $7.79, representing 16% year‑over‑year earnings growth and underscoring broad‑based strength across the portfolio. On the back of this start, the company raised its full‑year 2026 adjusted EPS guidance to at least $30.35, signaling confidence despite known headwinds.

Evernorth Growth Anchored by Solid Earnings

Evernorth revenues climbed 9% year‑over‑year to $58.4 billion in Q1 2026, supported by continued uptake of its health services platform. Pretax adjusted earnings reached $1.5 billion, slightly ahead of expectations, showing the segment can grow profitably even as it invests heavily in new models and client relationships.

Specialty and Care Services Drive High‑Margin Expansion

Specialty and Care Services delivered 20% year‑over‑year pretax adjusted earnings growth to $1.1 billion, highlighting the importance of higher‑margin clinical offerings within Evernorth. Management pointed to strong volume growth, increased use of biosimilars and specialty generics, and incremental contribution from the Shields Health Solutions investment as key earnings drivers.

Cigna Healthcare Delivers Strong Earnings and Favorable MCR

Cigna Healthcare generated pretax adjusted earnings of $1.5 billion on $11.5 billion in revenue, with earnings up 18% versus last year, reflecting disciplined underwriting and cost management. The business posted a medical care ratio of 79.8% in the quarter, better than expectations and providing cushion against expected seasonal normalization later in the year.

Improving Prior Authorization and Member Experience

Management highlighted a notable reduction in administrative friction, with hundreds of tests and procedures removed from prior authorization in the U.S., cutting medical prior authorization volume by roughly 15%. The company also underscored digital strengths, noting Cigna Healthcare ranked first in J.D. Power’s digital experience satisfaction for commercial members for a second straight year.

Innovation with Rebate‑Free Pharmacy and AI Usage

Cigna unveiled its “Signature” rebate‑free pharmacy service model, designed to offer brand drugs at prices about 30% lower with greater transparency, and early feedback from the Pharmacy Benefit Services selling season has been encouraging. The company is also leaning into data and AI, citing a predictive high‑cost claimant model that is generating around $2,000 in annual savings per engaged member.

Operational Efficiency and Digital Adoption Gains

Digital and AI‑enabled tools are translating into tangible operating efficiencies, with U.S. employer customers in Cigna Healthcare seeing a 20% reduction in inbound calls among digitally eligible members compared with two years ago. Pharmacy Benefit Services members also drove a 25% decline in inbound calls over the same period, supporting lower service costs and better scalability.

Capital Discipline and Balance Sheet Strength

The company generated $1.1 billion of operating cash flow in Q1 and ended the quarter with a debt‑to‑capitalization ratio of 42.3%, a 70‑basis‑point improvement from year‑end 2025. Cigna reiterated its balanced capital allocation framework, emphasizing reinvestment in the business alongside dividends and share repurchases while guiding to further leverage reduction by year‑end 2026.

Near‑Term Pressure in Pharmacy Benefit Services

Pharmacy Benefit Services pretax adjusted earnings fell 28% year‑over‑year to $394 million, representing roughly a $150 million quarterly decline driven by large client renewals and extensions, as well as upfront investments to transition to the new Signature model. Management framed this pressure as temporary and necessary to secure strategic contracts and accelerate the move to a more transparent, sustainable pharmacy economics.

Special Items Weigh on Reported Results

Cigna recorded after‑tax special items charges of $322 million in Q1 2026, equivalent to $1.22 per share, which weighed on reported earnings but are excluded from adjusted metrics. Executives portrayed these items as largely linked to ongoing transformation efforts and portfolio actions rather than underlying business performance.

Portfolio Exits and Strategic Reviews Reshape Scope

The company plans to exit the individual exchange business at year‑end and has initiated a strategic review of its eviCore operation, moves that narrow scope but aim to sharpen strategic focus. While these steps may trim near‑term revenue, management argued they will free up capital and attention for higher‑return growth areas across Evernorth and Cigna Healthcare.

Rising Noncontrolling Interests and JV Complexity

Noncontrolling interest climbed to $226 million in the quarter, more than doubling from the prior year period, largely due to a new joint venture with a major client that passes back additional economics. Executives acknowledged this adds modeling complexity and affects the split of earnings but emphasized that the impact was built into guidance and reflects attractive long‑term client partnerships.

Cash Flow Seasonality and Capital Flexibility

Operating cash flow in Q1 totaled $1.1 billion, with management reiterating that the bulk of 2026 cash generation will occur in the second half of the year, consistent with historical seasonality. This timing pattern may constrain near‑term capital deployment flexibility, but the company expects a stronger cash profile later in the year alongside lower leverage.

Forward‑Looking Guidance and Strategic Outlook

Cigna lifted its full‑year 2026 adjusted EPS guidance to at least $30.35 and expects Evernorth to deliver at least $6.9 billion in full‑year adjusted income from operations, with Q2 following typical seasonal patterns. Cigna Healthcare is projected to generate at least $4.525 billion in pretax adjusted earnings for the year, with a full‑year medical care ratio of 83.7% to 84.7% and a slightly elevated Q2 ratio, while longer‑term PBM plans target at least half of PBS members on Signature by the end of 2028.

Cigna’s earnings call painted a picture of a company leaning into growth businesses and innovative models while accepting near‑term friction in pharmacy benefits, special charges, and portfolio pruning. For investors, the key takeaways are resilient core earnings, an upgraded EPS outlook, heavy investment in transparency and AI‑driven efficiency, and a balance sheet positioned to support continued shareholder returns over time.